

1 Both COVID-19 infection and vaccination induce high-affinity cross- 2 clade responses to SARS-CoV-2 variants

3

4 Marc Emmenegger¹, Sebastian Fiedler², Silvio D. Brugger³, Sean R. A. Devenish², Alexey S. Morgunov^{2,4},
5 Alison Ilsley², Francesco Ricci², Anisa Y. Malik², Thomas Scheier³, Leyla Batkitar¹, Lidia Madrigal¹, Marco
6 Rossi⁵, Andrew K. Lynn², Lanja Saleh⁵, Arnold von Eckardstein⁵, Tuomas P. J. Knowles^{2,4,6}, Adriano
7 Aguzzi^{1&}

8 ¹ Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland

9 ² Fluidic Analytics, Unit A, The Paddocks Business Centre, Cherry Hinton Road, Cambridge CB1 8DH, United
10 Kingdom

11 ³ Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich,
12 Zurich, Switzerland

13 ⁴ Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield
14 Road, Cambridge CB2 1EW, United Kingdom

15 ⁵ Laboratory Medicine, University Hospital Zürich, Switzerland

16 ⁶ Cavendish Laboratory, Department of Physics, University of Cambridge, JJ Thomson Ave, Cambridge, CB3 0HE,
17 United Kingdom

18 & Corresponding author: adriano.aguzzi@usz.ch

19

20 Abstract

21 The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using
22 microfluidics-based antibody affinity profiling (MAAP), we have recently shown that current
23 therapeutic monoclonal antibodies exhibit a drastic loss of affinity against omicron. Here, we have
24 characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories
25 of SARS-CoV-2 infection and/or vaccination as well as in 2 subjects without vaccination or infection.
26 Antibody affinity in patient plasma samples was similar against the wild-type, delta, and omicron
27 variants (K_A ranges: 122 ± 155 , 159 ± 148 , $211\pm 307 \mu\text{M}^{-1}$, respectively), indicating a surprisingly broad
28 and mature cross-clade immune response. We then determined the antibody iso- and subtypes
29 against multiple SARS-CoV-2 spike domains and nucleoprotein. Postinfectious and vaccinated subjects
30 showed different profiles, with IgG3 ($p = 0.002$) but not IgG1, IgG2 or IgG4 subtypes against the spike
31 ectodomain being more prominent in the former group. Lastly, we found that the ELISA titers against
32 the wildtype, delta, and omicron RBD variants correlated linearly with measured IgG concentrations
33 ($R=0.72$) but not with affinity ($R=0.29$). These findings suggest that the wild-type and delta spike
34 proteins induce a polyclonal immune response capable of binding the omicron spike with similar
35 affinity. Changes in titers were primarily driven by antibody concentration, suggesting that B-cell
36 expansion, rather than affinity maturation, dominated the response after infection or vaccination.

37

38 Key words

39 SARS-CoV-2 B.1.1.529, Omicron, antibody affinity, antibody typing, exploratory data analysis

40

41 Introduction

42 The SARS-CoV-2 B.1.1.529 variant (omicron), considered a WHO variant of concern due to its high
43 transmission rate and its large number of mutations (Han *et al.*, 2022), has become the predominant
44 viral lineage across the globe in early 2022. Its 34 mutations in the spike protein, 15 of which are
45 located within its receptor binding domain (RBD) which interacts with ACE2, have been shown to
46 impact neutralization (1) of therapeutic monoclonal antibodies in pseudotyped virus-based assays
47 (Cao *et al.*, 2021; Cele *et al.*, 2021; Planas *et al.*, 2021; VanBlargan *et al.*, 2022), (2) of serum antibodies
48 of convalescent patients infected with previous strains, and (3) of serum antibodies of double-
49 vaccinated individuals who had been vaccinated with BNT162b2 (Pfizer-BioNTech), mRNA-1273
50 (Moderna), Ad26.COV2.S (Johnson & Johnson), ADZ1222 (Astra Zeneca), Sputnik V, or BBIBP-CorV
51 (Sinopharm) (Planas *et al.*, 2021; Cameroni *et al.*, 2022; Dejnirattisai *et al.*, 2022; Edara *et al.*, 2022;
52 Liu *et al.*, 2022). While triple vaccination with BNT162b2 or mRNA-1273 or a combination between
53 infection with WT or delta SARS-CoV-2 followed by vaccination increased neutralizing potency
54 compared to double-vaccinated or convalescent serum, titers were still drastically lower for omicron
55 compared with WT or delta SARS-CoV-2 (Planas *et al.*, 2021; Cameroni *et al.*, 2022; Dejnirattisai *et al.*,
56 2022; Edara *et al.*, 2022; Liu *et al.*, 2022).

57 The antibody response against one or multiple epitopes, elicited upon infection or vaccination is
58 characterized by two properties: affinity and concentration. Those are fundamental, well-defined
59 biophysical parameters; however, until recently it has been challenging to measure them directly in
60 complex heterogeneous mixtures, like serum or plasma. We have recently employed Microfluidic
61 Antibody Affinity Profiling (MAAP) to simultaneously determine the affinity and concentration of
62 antibodies against WT RBD in convalescent sera (Schneider *et al.*, 2022), to study the antibody-based
63 inhibition of RBD-ACE2 interactions (Fiedler *et al.*, 2021) and to understand memory re-activation and
64 cross-reactivity (Denninger *et al.*, 2021). We have also characterized the affinity of multiple
65 therapeutic antibodies (cilgavimab, tixagevimab, casirivimab, and imdevimab) to the omicron RBD
66 variant (Fiedler *et al.*, 2022). While most of these antibodies exhibited a striking loss of affinity, a
67 pooled plasma standard of anti-SARS-CoV-2 immunoglobulins (Mattiuzzo *et al.*, 2020) retained
68 substantial cross-reactivity to the omicron spike RBD with only moderately decreased antibody
69 concentration and affinity against the omicron variant (Fiedler *et al.*, 2022).

70 Here, we determined the antibody fingerprints in 39 pre-omicron and two uninfected/non-vaccinated
71 control patients admitted to the University Hospital Zurich, Switzerland. Patients included in this study
72 had a variety of disease trajectories (including no COVID-19) and had received between zero and three
73 doses of vaccine. Using MAAP, we first analyzed antibody affinity and concentration against WT, delta,
74 and omicron RBD variants. We then assessed the impact of vaccination or infection, alone or in

75 combination, as well as of other parameters such as age or disease severity, to antibody concentration
76 and affinity. Lastly, we characterized the antibody isotype and subtype compositions against SARS-
77 CoV-2 spike domains and against the nucleocapsid (NC) protein using a miniaturized enzyme-linked
78 immunoassay (ELISA) for SARS-CoV-2 antigens called TRABI (Emmenegger *et al.*, 2020, 2021). We
79 found that the natural humoral responses of pre-omicron patients showed less severe reductions of
80 antibody affinity than was observed with monoclonal antibodies and we speculate that this is due to
81 the polyclonal nature of the infection- or vaccination-induced humoral immune response.
82 Additionally, we found that ELISA-based antibody titers correlated with IgG concentrations but not
83 with affinity, and the antibody profiles in vaccinated but non-infected patients were different from
84 those of patients with a history of SARS-CoV-2 infection.

85

86 Results

87 Study design and experimental approach.

88 We have recently described a powerful microfluidics-based technology that enables the affinity
89 determination of complex antibody mixtures in solution in plasma samples (Schneider *et al.*, 2022).
90 Our finding that affinity of therapeutic monoclonal antibodies are markedly decreased against the
91 SARS-CoV-2 omicron RBD variant (Fiedler *et al.*, 2022) prompted us to investigate the anti-omicron
92 affinity of serum responses in patients who had suffered from pre-omicron COVID-19, or were
93 vaccinated with pre-omicron vaccines.





Fig. 1

Figure 1. Study design and experimental approach. **A.** Flowchart for inclusion and exclusion into the study. 41 samples were included in the analysis, representing different patient groups. **B.** Violin boxplot showing distribution of IgG p(EC₅₀) values against the SARS-CoV-2 spike protein. A cutoff value of p(EC₅₀) ≥ 2 was chosen to define reactive samples. Blue dots represent samples of infected and/or vaccinated individuals. Yellow dots are non-infected and non-vaccinated negative controls.

94 We collected heparin plasma samples of 50 individuals (pre-omicron) admitted to our hospital. One
95 sample was hemolytic and was excluded from further analyses (**Fig. 1A**). Forty-nine samples were
96 tested for IgG reactivity against the SARS-CoV-2 WT spike protein using the TRABI technology
97 (Emmenegger *et al.*, 2020, 2021). We set a cutoff of p(EC₅₀) ≥ 2 for inclusion in subsequent analyses.
98 Eight samples did not reach this threshold and were excluded (**Fig. 1B**). The remaining 41 samples
99 comprised two patients without prior infection/vaccination, eight patients who had suffered SARS-
100 CoV-2 infection but had not received any vaccination, 20 patients who had never been infected with
101 SARS-CoV-2 but received vaccinations (BNT162b2 or mRNA-1273) and 11 patients with previous SARS-
102 CoV-2 infection and vaccination (see **Table 1**). The presence of infection, prior or at the time of
103 sampling, was inferred based on medical history and/or one or multiple positive SARS-CoV-2 RT-qPCR.
104 The median age of enrolled patients was 65 (interquartile range (IQR): 54-77) years. Among the
105 patients with a history of infection (n=19), the median days post-onset of disease manifestation (DPO)



106 was 12 (IQR: 8.25-17.75) days. For five patients whose infection dated back more than a month before
 107 sampling, the exact DPO could not be inferred from the clinical record. These samples were analyzed
 108 using MAAP (Denninger *et al.*, 2021; Fiedler *et al.*, 2022; Schneider *et al.*, 2022) with SARS-CoV-2
 109 wildtype (WT), delta, and omicron RBD variants. Antibody isotypes and subtypes were further
 110 assessed in the same samples using TRABI (Emmenegger *et al.*, 2020, 2021).

111 Characterization of affinity of SARS-CoV-2 antibodies to WT, delta, and omicron RBD 112 variants.

113 We measured the affinities and concentrations of patient samples to WT, delta, and omicron RBD. We
 114 report the affinity constant (K_A), which is $1/K_D$, where K_D is the equilibrium dissociation constant.
 115 Measured antibody affinity constants ranged between $3.59 \mu M^{-1}$ (K_D : 278 nM, i.e. comparatively low

116 affinity) and $943.3 \mu\text{M}^{-1}$ (K_D : 1 nM, i.e. comparatively high affinity). Thus, we observed an
 117 approximately 250-fold affinity range within our cohort. The IgG concentrations varied between 3 and
 118 49,074 nM (range: $4.2 \log_{10}$) (**Fig. 2A**). The integrated 2D-density plot revealed a moderate left shift,
 119 i.e. overall decreased K_A , of antibodies to omicron while none of the variants formed separate clusters




Fig. 3

Figure 3. Correlation of affinity and IgG concentrations with clinically relevant parameters does not reveal clear differences between vaccinated and infected subgroups. **A.** 2D scatter plot with integrated density contours. All quantifiable data points reflecting K_A (in M^{-1}) and IgG concentration (in M) are plotted. 95% confidence intervals for each point are colored in light red. No distinct clusters were observed among patient groups infected/vaccinated (grey), infected/non-vaccinated (blue), non-infected/vaccinated (yellow), however, the REGN-COV-treated patients (red) clustered separately. **B.** The same groups as in (A) depicted in a boxplot. Statistical analysis is shown in the graph. The RBD variants are color-coded. **C** and **D.** No correlation between age (C) or sex (D) and $K_A \times \text{IgG}$ concentration. **E.** While Kruskal-Wallis statistical testing indicates that the distributions are significantly different for different disease severities, pair-wise testing with Wilcoxon rank sum test does not result in significance. **F.** Trend towards increased $K_A \times \text{IgG}$ concentration products in triple vaccinated individuals, without being statistically significant. A: Dotted lines represent the measurements of the same patient sample against different RBD variants. B, D-F: Kruskal-Wallis (KW) with post-hoc Wilcoxon rank sum test (WC) after Holm correction for multiple comparisons was used, with $\alpha = 0.01$. C: The Pearson correlation coefficient was calculated. C-F: The patient groups are color-coded as in (A), however, the REGN-COV-treated patients were excluded from analyses.

120 and mostly overlapped. 49% of samples could not be quantified in terms of K_A or IgG concentration
121 for omicron (33% for wildtype and 36% for delta) (**Fig. 2B**). However, the distributional differences of
122 quantifiable/non-quantifiable samples did not significantly differ (Fisher's exact test, $\alpha = 0.01$) among
123 any of the antigens, for all samples ($n=39$), for those with an exclusively infection- and/or vaccine-
124 induced antibody response ($n=34$), or for those treated with the REGN-COV cocktail (casirivimab and
125 imdevimab, $n=5$), although a trend towards increased evasion of antibody binding for omicron was
126 visible.

127 We then investigated K_A (**Fig. 2C**), IgG concentrations (**Fig. 2D**) and the product of $K_A \times$ IgG
128 concentration (**Fig. 2E**) for the three RBD variants. None of the variants displayed a statistically
129 significant deviation (Kruskal-Wallis with post-hoc Wilcoxon rank sum test after Holm correction for
130 multiple comparisons, with $\alpha = 0.01$). Five patients who received the REGN-COV antibody cocktail
131 displayed the highest IgG concentrations measured, yet their affinities were in the range of the non-
132 REGN-COV-treated patients (**Fig. 2A, 2C-E**). In sum, the antibody response following infection and/or
133 vaccination appears less susceptible to a drastic loss in binding against the omicron variant compared
134 to monoclonal antibodies.

135 [Correlation of antibody fingerprints with clinically relevant parameters does not reveal
136 clear differences between vaccinated and infected subgroups.](#)

137 We next characterized the affinity/concentration profiles in four patient groups: (1) infected/non-
138 vaccinated; (2) non-infected/vaccinated; (3) infected/vaccinated; (4) treated with REGN-COV. We
139 studied the same profile as above, but we color-coded the data points according to the groups of
140 patients (**Fig. 3A**). The patients treated with the REGN-COV cocktail clustered separately as expected,
141 whereas the density representations for vaccinated and/or infected patient groups were largely
142 overlapping. Statistical testing showed that the $K_A \times$ IgG concentration product significantly differed in
143 patients treated with the REGN-COV cocktail versus all other groups (Wilcoxon rank sum test after
144 Holm correction, **Fig. 3B**). However, the profiles observed following vaccination and/or infection did
145 not statistically differ among each other. In the following analyses, we have focused solely on those
146 groups with physiological antibody responses and excluded the REGN-COV-treated patients.
147 Correlations of $K_A \times$ IgG concentration with age (**Fig. 3C**, the Pearson correlation coefficient R was
148 calculated for the three groups), sex (**Fig. 3D**) or with disease severity (**Fig. 3E**) revealed heterogeneity
149 rather than marked differences. The Kruskal-Wallis test indicated significant distributional differences
150 as a function of disease severity (p -value=0.0084), yet, pair-wise testing with Wilcoxon rank sum test
151 did not result in any significantly changed group after correcting for multiple comparisons. While we
152 observed a trend towards increased $K_A \times$ IgG concentration with a higher number of vaccinations (**Fig.**
153 **3F**), the distributions did not significantly differ. In conclusion, multiple vaccinations and the

154 combinations of infections and vaccinations do not exert an immediately measurable effect on
 155 fundamental biophysical properties such as K_A and IgG concentrations in the complex samples used in
 156 this study.




Fig. 4

157 [Analysis of antibody subtypes, correlation with affinity and global feature profiling.](#)

158 As infection, vaccination or parameters such as disease severity, age, and number of vaccinations did
159 not clearly correlate with antibody affinity or concentration, we aimed to obtain a more granular view
160 of the antibody compositions. Thus, we used TRABI (Emmenegger *et al.*, 2020, 2021) to deeply
161 characterize the antibody iso- and subtypes in our patient collective, to compare it to antibody affinity
162 and concentration, and to seek potential clinical or demographic correlates.

163 We first measured IgG, IgA, IgM, IgG1, IgG2, IgG3, and IgG4 antibodies against the SARS-CoV-2 WT
164 spike ectodomain (ECD), the WT S1 domain, the WT S2 domain, the WT RBD, the delta RBD, and the
165 omicron RBD variants as well as the nucleocapsid (NC) proteins and illustrate them in a heatmap (**Fig.**
166 **4A**, purple gradients). The antibody profile mainly revealed that the antibody response, in general, is
167 dominated by IgG, followed by IgA and much less so by IgM and that all IgG subtypes, except IgG2,
168 contributed to the IgG response against the spike-associated domains (**Fig. S1A**). The presence of IgG
169 antibodies against the NC, the only protein employed here that is not intrinsically connected to the
170 spike ECD, is indicative of an infection, which was observed in almost all patients with clinically
171 characterized infection with SARS-CoV-2. For NC, the dominant IgG subtype was IgG3 (**Fig. S1B**).

172 To validate our results, we repeated the IgG4 measurements against the entire collection of antigens,
173 with the same IgG4-specific secondary antibody (**Fig. S1C**) and with the same clone but different
174 storage buffer sold by a different vendor (**Fig. S1D**). We observed robust correlations using the same
175 IgG4-specific secondary antibody (Pearson correlation coefficient $R=0.94$) as well as the same antibody
176 clone from a different source (Pearson correlation coefficient $R=0.93$) in three fully independent
177 experiments. Moreover, the IgG titers measured for the three RBD variants via ELISA correlated well
178 among each other (**Fig. S2A-C**) and with the spike protein (**Fig. S2D**) Similarly, the immunoglobulin iso-
179 and subtype compositions have been largely congruent for the three RBD variants, as shown using the
180 mean $p(EC_{50})$ values (**Fig. S2E**).

181 We then included additional features such as the K_A values, the IgG concentrations, age, sex,
182 indications for treatment with REGN-COV antibodies, immunosuppression (none, light, heavy), the
183 DPO as well as disease severity, and aligned these values for each patients, separated into the
184 vaccination/infection groups (**Fig. 4A**). This view offers a comprehensive multidimensional assessment
185 of many parameters at the single-individual level. We first correlated the IgG ELISA $p(EC_{50})$ values
186 obtained against WT, delta, and omicron RBD with the respective MAAP-derived K_A , the IgG
187 concentration, and the product $K_A \times$ IgG concentration (**Fig. 4B**, and **Fig. S3** for a general
188 representation). While K_A showed no linear relationship with ELISA titers (average R over all
189 groups= 0.29 , p -value= 0.015), both IgG concentration (average R over all groups= 0.72 , p -value= $5.4 \times$

190 10^{-13}) as well as the MAAP product (average R over all groups=0.71, p-value= 5.4×10^{-12}) were well
191 represented by a linear model, for all the three variants. This finding suggested that the titers observed
192 in ELISA primarily reflect antibody concentrations rather than affinities in samples analyzed here.

193 We then reduced the dimensionality across all measured antibodies using principal component
194 analysis (PCA) and projected the linear combinations in two-dimensional space (**Fig. 4C**, and **Fig. S4**
195 for a granular view on the variable map). We used three representations using colors and shapes: (1)
196 The infection/vaccination cohorts, where we included patients treated with the REGN-COV antibodies,
197 (2) the number of vaccinations (excluding REGN-COV), (3) disease severity (excluding REGN-COV).
198 Regional clusters of specific antibody iso- and subtypes were annotated in black. Black shapes indicate
199 the mean points of a given group (indicated by color and shape). PCA suggested that while patients
200 with infection (infected/non-vaccinated; infection/vaccinated) clustered towards spike-associated
201 (annotated as S*) IgG3 as well as NC IgG, IgG1, IgG3, and IgA, patients with vaccination (non-
202 infected/vaccinated: infected/vaccinated) clustered towards spike-associated IgG4. Spike-associated
203 IgG as well as IgG1 were between the two groups. Moreover, a higher number of vaccinations (two or
204 three) appeared to be linked to spike-associated IgG4 positivity, while fewer vaccinations (none or
205 one) clustered more closely to spike-associated IgG3 as well as to NC IgG, IgG1, IgG3, and IgA. A largely
206 similar pattern was observed with disease severity. No or mild disease clustered more in the region of
207 spike-associated IgG4 while more severe disease courses (hospitalization, oxygen supplementation,
208 ICU) assembled in the region of spike-associated IgG3 and the NC sub- and isotypes referred to above.
209 In sum, this representation evidenced an association between infection, more severe disease, absence
210 of vaccinations, and an IgG3 response against the spike-associated proteins. Conversely, the IgG4
211 response against spike-associated proteins was mainly characterized by vaccination, with higher
212 repeats of vaccinations, and a less severe disease course on average.

213 [Multidimensional analysis suggests slightly different antibody profiles in patients after](#)
214 [SARS-CoV-2 infection versus vaccination alone.](#)

215 Based on the patterns identified above, we analyzed potential associations using different methods.
216 We first calculated the Pearson correlation coefficients for all antigens and antibody iso- and subtypes
217 and included additional parameters such as disease severity, immunosuppression, the REGN-COV
218 cocktail, the number of vaccinations, sex, and age, and plotted the significant correlations in a
219 correlogram (**Fig. 5A**). Globally, the correlogram indicated a pronounced positive correlation within
220 the iso- or subtypes, which is expected as all domains are contained within the spike ECD, except the
221 NC antigen. IgG1 correlated almost perfectly with IgG, while IgM and IgG2 displayed only spurious
222 correlation with IgG. Disease severity correlated with reactivity against the NC protein, for IgG, IgA,
223 IgG1, and foremostly IgG3 but not for IgG2 or IgG4. A higher number of vaccinations showed negative

224 correlations with NC for IgA and IgG1. Sex and age did not display strong correlations in any direction.
 225 The same correlogram with all correlations irrespectively of the significance level is shown in **Fig. S5**.




Fig. 5

Figure 5. Multidimensional analysis of antibody profiles in patients after SARS-CoV-2 infection versus vaccination. A. Correlogram analysis using the TRABI ELISA values combined with features such as disease severity, immunosuppression, number of vaccinations received, sex, and age. Only significant correlations are shown, at $\alpha = 0.01$. **B.** Ridge plot distributions of $p(EC_{50})$ values for all immunoglobulin iso- and subtypes against the Spike ECD. Data was aggregated according to patient group, vaccination, number of vaccinations, infection, disease severity, and immunosuppression. Kruskal-Wallis (KW) with post-hoc Wilcoxon rank sum test (WC) after Holm correction for multiple comparisons was used, with $\alpha = 0.01$. Only significant changes are displayed.

226 We then looked into the antibody reactivity profiles that have shown relevance based on the PCA
227 representation and the correlogram. The $p(EC_{50})$ values of seven Ig iso- and subtypes for the SARS-
228 CoV-2 spike ECD were represented as a ridge plot. We focused only on the spike protein as a well-
229 correlated surrogate for other spike domains (see **Fig. S2D**), and omitted the NC protein from this
230 analysis. We compared the groups per antibody iso- and subtype looking at the entire distribution by
231 means of Kruskal-Wallis test with post-hoc Wilcoxon rank sum test corrected for multiple comparisons
232 with Holm ($\alpha=0.01$). Exclusively significant distributional differences were annotated in the in the plot
233 (see **Fig. 5B**). Kruskal-Wallis statistics indicated that the IgG responses of the non-infected/vaccinated
234 groups showed a significant change among each other (p -value=0.0024), however, the group-wise
235 testing by means of the Wilcoxon rank sum test did not reach statistical significance due to multiple
236 comparisons that were performed. Likewise, the IgG distributions differed among the degrees of
237 severity (p -value=0.0076, Kruskal-Wallis), but pair-wise testing resulted in non-significant differences
238 While the IgG4, but not overall IgG, IgG1, IgG2, or IgG3 distributions of patients after vaccination
239 showed a trend towards higher $p(EC_{50})$ values, which were increased after three vaccinations, this
240 observation did not reach statistical significance. However, infection was associated with higher
241 $p(EC_{50})$ values for IgG (p -value=0.00028, Wilcoxon rank sum test after Holm correction), and IgG3 (p -
242 value=0.002, Wilcoxon) but not for IgG1, IgG2 or IgG4.

243

244 Discussion

245 We reported that the monoclonal antibodies deployed against previous variants of SARS-CoV-2 show
246 drastically reduced affinity against the omicron variant (Fiedler *et al.*, 2022). Here, we found that delta-
247 infected and/or vaccinated subjects develop plasma antibodies with similar affinities to all major
248 SARS-CoV-2 clades. Previous SARS-CoV-2 infection (alone or in combination with vaccination), but not
249 vaccination alone, was associated with higher overall anti-SARS-CoV-2 spike IgG, and IgG3 titers. Thus,
250 although antibody profiles following infection differs from that of vaccinated patients who did not
251 encounter the virus, pre-omicron responses showed impressive cross-clade affinities.

252 The high-affinity responses to the omicron spike protein contrast starkly with those of current
253 therapeutic monoclonal antibodies (Fiedler *et al.*, 2022) whose neutralization of omicron was poor or
254 absent (Dejnirattisai *et al.*, 2021; Planas *et al.*, 2021; VanBlargan *et al.*, 2022). The K_A of plasma
255 antibodies against SARS-CoV-2 RBD variants were in a similar range of 16.9-684.9 μM^{-1} for WT, 13.5-
256 471.7 μM^{-1} for delta, and 3.6-943.4 μM^{-1} for omicron. These data may provide an explanation for the
257 observation that patient sera after three doses of the Pfizer-BioNTech mRNA vaccine and convalescent
258 individuals after a Pfizer-BioNTech booster retained neutralization capacity against omicron (Planas *et*
259 *al.*, 2021).

260 As expected, the spike-specific IgG concentrations of the REGN-COV cocktail administered to patients
261 exceeded the IgG concentrations following a genuine immune response triggered by infection or
262 vaccination by approximately 30-fold and the $K_A \times \text{IgG}$ concentration product was significantly
263 different in the group treated with REGN-COV versus all other groups. However, we did not identify
264 any significant correlate between K_A or IgG concentrations and parameters such as infection or
265 vaccination, alone or in combination, the number of vaccinations, the severity of disease, or with sex
266 and age.

267 To increase the depth in our data set, we added data complementary to antibody affinity and
268 concentrations and mapped the contributions of different iso- and subtypes measured by TRABI ELISA
269 (Emmenegger *et al.*, 2020, 2021), using a comprehensive panel of antigens (WT spike ectodomain, WT
270 spike S1, WT spike S2, WT RBD, delta RBD, omicron RBD, NC protein). We observed that the $p(\text{EC}_{50})$
271 values of the RBD variants derived by ELISA correlated well with each other, in line with affinity
272 measurements, as well as with the WT spike. However, while ELISA titers correlated poorly with
273 affinity measurements, they were in excellent agreement with the IgG concentrations. Hence antibody
274 titers measured in ELISA, typically a conflation of both affinity and concentration, were mostly driven
275 by concentrations rather than affinities. Most likely this is because at an estimated ELISA plate surface-
276 bound RBD concentration of about 480 nM, the expected [antibody-RBD] complex concentration is

277 much more sensitive to antibody concentration than to antibody affinity, provided that antibody
278 concentrations exceed K_D . At low affinities (high K_D values) close to the measured antibody
279 concentration or if the antibody concentrations drop to about the K_D or lower, the [antibody-RBD]
280 complex concentration becomes much more sensitive to affinity. At a mean K_D of 6 nM and IgG
281 concentration of 1 μ M in our dataset (across all RBD variants measured), our immobilization-based
282 ELISA measurements are thus mostly influenced by antibody concentration.

283 Several patients had IgG4 antibody titers against spike domains, but not against the NC, a
284 phenomenon which had not been reported to the same extent (Amanat *et al.*, 2020; Suthar *et al.*,
285 2020; Klingler *et al.*, 2021; Kober *et al.*, 2022; Sievers *et al.*, 2022) although IgG4 antibodies against
286 spike domains have been reported (Farkash *et al.*, 2021; Jarlhelt *et al.*, 2021). Our observation was
287 corroborated by repeating the measurements using the same IgG4-specific secondary antibody as well
288 as by using the same clone from an alternative source (including differences in concentrations and
289 storage buffers), which makes us confident that the results presented are valid. The higher prevalence
290 of the IgG4 subtype might arise due to repeated encounters with the antigen, which earlier studies
291 may not have captured.

292 We next explored the antibody profiles using a feature-based dimensionality reduction and
293 comprehensive correlograms. Both approaches pointed towards a slightly altered antibody profile
294 following vaccination or infection, with a stronger IgG3 response upon infection. However, the clusters
295 were relatively weak and potentially ambiguous in our dataset, although a previous investigation
296 derived similar conclusions regarding differences in the profiles between vaccinated and convalescent
297 individuals (Klingler *et al.*, 2021). Therefore, we focused on WT spike ECD, by looking at the distribution
298 in a statistical manner. We confirmed that infection alone or in combination with vaccination was
299 associated with higher $p(EC_{50})$ values for IgG and IgG3 but not for IgG1, IgG2 or IgG4.

300 The limitations of our investigations reside in the number of patients enrolled in the study and the
301 vast number of variables reported, which may constrain the generalizability of results and conclusions.
302 Therefore, all variables underlying this study are available for further studies and for comparison with
303 future cohorts. On the other hand, our findings describing the antibody response of pre-omicron
304 convalescent or post-vaccination sera to the SARS-CoV-2 omicron variant are congruent with those
305 found by others with other methods, including viral neutralization and clinical observations.

306 In conclusion, we have investigated antibody affinity and concentration following infection and/or
307 vaccination in the presence of an antigenic drift. We found that the tolerance to the omicron drift was
308 surprisingly robust, whereas the currently approved therapeutic monoclonal antibodies lost much of
309 their affinity. The most plausible scenario is that antibodies are selected in vivo for immunodominant

310 spike domains that are invariant between clades of virus, whereas therapeutic monoclonals were
311 presumably selected in vitro for highest affinity but not for cross-clade protection. Ultimately, our
312 finding, along with others, suggests that the B-cell-mediated immunity, possibly concomitant with a
313 T-cell response, elicited upon infection and/or vaccination might be broad enough to confer a layer of
314 protection in the event of further waves of mutated SARS-CoV-2 variants.

315

316 Methods and Materials

317 Ethics statement.

318 For this study, we included residual pre-omicron heparin plasma samples from patients admitted to
319 the University Hospital Zurich, Zurich, Switzerland, whose blood was sent to the Institute of Clinical
320 Chemistry for routine diagnostic procedures. Infections with the SARS-CoV-2 B.1.1.529 variant were
321 excluded by means of dropout PCR. All experiments and analyses involving samples from human
322 donors were conducted with the approval of the ethics committee of the canton Zurich, Switzerland
323 (KEK-ZH-Nr. 2015-0561, BASEC-Nr. 2018-01042, and BASEC-Nr. 2020-01731), in accordance with the
324 provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International
325 Conference on Harmonisation. All subjects enrolled in the study signed the hospital-wide General
326 Consent of the University Hospital Zurich, Switzerland.

327 Fluorescent labeling of proteins

328 Recombinant proteins were labeled with Alexa Fluor 647 NHS ester (Thermo Fisher) as described
329 previously (Fiedler *et al.*, 2021, 2022). In brief, solution containing 150 µg of spike RBD was mixed with
330 dye at a three-fold molar excess in the presence of NaHCO₃ (Merck) buffer at pH 8.3 and incubated at
331 4 °C overnight. Unbound label was removed by size-exclusion chromatography (SEC) on an ÄKTA pure
332 system (Cytiva) using a Superdex 75 Increase 10/300 column (Cytiva). Labeled and purified proteins
333 were stored at -80 °C in PBS pH 7.4 containing 10% (w/v) glycerol as cryoprotectant.

334 Antibody affinity and concentration determination.

335 Microfluidic Antibody Affinity Profiling (MAAP) measurements were performed as reported previously
336 (Schneider *et al.*, 2022). For the MAAP measurements, varying fractions of human plasma samples
337 were added to a solution of the antigen of concentrations varying between 1 nM and 400 nM, and a
338 buffer containing PBS at pH 7.4, 0.05% (w/v) Tween 20 (Merck), 5% (w/v) human serum albumin
339 (Merck), and 10% (w/v) glycerol (Merck). The antigens used were RBD (Sino Biological; WT 40592-
340 V08H, Delta 40592- V08H90, Omicron 40592- V08H121) labelled with Alexa Fluor™ 647 (Thermo
341 Fisher) through amine coupling. These samples were incubated on ice for 30 minutes and the size of
342 the formed immunocomplex was determined through measuring the hydrodynamic radius, R_h , with
343 Microfluidic Diffusional Sizing (MDS) using the commercial Fluidity One-M platform. The data were
344 analysed by Bayesian inference as described previously (Linse *et al.*, 2020; Schneider *et al.*, 2022).

345 ELISA.

346 Serological ELISAs were carried out as previously described (Emmenegger *et al.*, 2020, 2021) with
347 minor adjustments. High-binding 1,536-well plates (Perkin-Elmer; SpectraPlate 1536 HB) were coated
348 with 3 µL of 1 µg/mL SARS-CoV-2 spike ECD, WT S1, WT S2, WT RBD, delta RBD, omicron RBD, or NC
349 protein in PBS using Fritz Gyger Certus Flex, incubated at 37 °C for 1 h in a ThermoFisher rotating plate

350 incubator, and washed three times with PBS 0.1% Tween-20 (PBS-T) using Biotek EI406. Plates were
351 blocked with 10 μ L of 5% milk in PBS-T for 1.5 h using Biotek Multiflo FX peristaltic dispensing
352 technology. Samples inactivated with 1% Triton X-100 and 1% tributyl phosphate were diluted in
353 sample buffer (1% milk in PBS-T), and a serial dilution (range: 0.02 to 1.6×10^{-4}) was carried out
354 (volume: 3 μ L per well) on an ECHO 555 acoustic dispenser (Labcyte) using contactless ultrasound
355 nanodispensing. After the sample incubation for 2 h at RT, the wells were washed five times with wash
356 buffer, and the presence of anti-SARS-CoV-2 antibodies was detected using horseradish peroxidase
357 (HRP)-linked antibodies (1. anti-human IgG antibody: Peroxidase AffiniPure Goat Anti-Human IgG, Fcy
358 Fragment Specific; Jackson; 109-035-098 at 1:4,000 dilution. 2. anti-human IgA antibody: Goat Anti-
359 Human IgA Heavy Chain Secondary Antibody, HRP; Thermo Fisher Scientific; 31417 at 1:750 dilution.
360 3. anti-human IgM antibody: anti-human IgM μ -chain-specific antibody; Sigma-Aldrich; A6907 at
361 1:3,000 dilution. 4. anti-human IgG1 antibody: mouse anti-human IgG1 Fc-HRP; Southern Biotech;
362 9054-05 at 1:3,000 dilution. 5. anti-human IgG2 antibody: mouse anti-human IgG2 Fc-HRP; Southern
363 Biotech; 9060-05 at 1:3,000 dilution. 6. anti-human IgG3 antibody: mouse anti-human IgG3 Hinge-
364 HRP; Southern Biotech; 9210-05 at 1:3,000 dilution. 7. anti-human IgG4 antibody: mouse anti-human
365 IgG4 Fc-HRP; Southern Biotech; 9200-05 at 1:3,000 dilution), all of them diluted in sample buffer at 3
366 μ L per well dispensed on Biotek Multiflo FX. The incubation of the secondary antibody for 1 h at RT
367 was followed by three washes with PBS-T, the addition of 3 μ L per well of Tetramethylbenzidine (TMB)
368 substrate solution with a Fritz Gyger Certus Flex dispenser, incubation of 3 min at RT, and the addition
369 of 3 μ L per well 0.5 M H₂SO₄ using Fritz Gyger Certus Flex. The plates were centrifuged in the Agilent
370 automated microplate centrifuge after all dispensing steps, except for the addition of TMB. The
371 absorbance at 450 nm was measured in a plate reader (Perkin-Elmer; EnVision), and the inflection
372 points of the sigmoidal binding curves [i.e., the $p(EC_{50})$ values of the respective sample dilution; $p(EC_{50})$
373 is the negative logarithm of one-half the maximal concentration (EC_{50})] were determined using a
374 custom-designed fitting algorithm (Emmenegger *et al.*, 2020), with plateau and baseline inferred from
375 the respective positive and negative controls in a platewise manner. Negative $p(EC_{50})$ values, reflecting
376 nonreactive samples, were rescaled as zero.

377 For quality testing, the same procedure was applied as above using the same clone (HP6025) of the
378 HRP-linked secondary antibody but from a different vendor, including a different storage buffer:
379 mouse anti-human IgG4; Invitrogen; A-10654 at 1:500 dilution.

380 [Statistics and data analysis.](#)

381 When looking at continuous distributions, tests were performed using the `compare_means()` function
382 of the `ggpubr` package 0.4.0 in R. The method chosen was Kruskal-Wallis (`method=kruskal.test`) with
383 subsequent Wilcoxon rank sum test (`method=wilcox.test`) with Holm correction for multiple

384 comparisons, comparing groups with $\alpha < 0.01$ for Kruskal-Wallis against all other groups. Comparisons
385 where $\alpha < 0.01$ with Wilcoxon rank sum test were annotated. Fisher's test was conducted in Graph
386 Pad Prism, with $\alpha < 0.01$.

387 Principal component analysis was performed using the `prcomp()` function as a part of the stats (version
388 3.6.2) package in R, with `center = TRUE` und `scale = FALSE`. The data was then visualised using
389 `fviz_pca_biplot()` from the `factoextra` library. The correlation matrix was computed using the `cor()`
390 function (part of the stats (version 3.6.2) package) in R and visualised as a correlogram using the
391 `corrplot()` function in the `corrplot` package in R. The p-values of the correlations were computed using
392 the `cor.test()` function (part of the stats (version 3.6.2) package) for the Pearson correlation coefficient
393 and $\alpha < 0.01$ was chosen for significance.

394 For visualisation of individual data points in boxplots, violin plots, ridge plots (`ggridges` package),
395 density plots (with `geom_density_2d` where a 2D kernel density estimation was performed on the X
396 and Y coordinates of the input data and the results were displayed with contours), heatmaps (using
397 `heatmap.2`, a part of the `gplots` 3.1.1 library), and as scatter dot plots, `ggplot2` (version 3.3.5) functions
398 were used. Regression lines and 95% confidence intervals were calculated in `ggplot2` and regression
399 coefficients were computed using the `stat_cor()` function a part of the `ggpubr` (version 0.4.0)
400 package. Radar plots were generated with the `fmsb` package (version 0.7.3) in R.

401 [HRP-conjugated antibodies used.](#)

402 See **Table 2**.

403 *Table 2. HRP-conjugated antibodies used,*

Species	Target	Dilution	Brand name	Product number
Goat	anti-human IgG	1:4,000	Jackson	109-035-098
Goat	anti-human IgA	1:750	Thermo Fisher Scientific	31417
Goat	anti-human IgM	1:3,000	Sigma-Aldrich	A6907
Mouse	anti-human IgG1	1:3,000	SouthernBiotech	9054-05
Mouse	anti-human IgG2	1:3,000	SouthernBiotech	9060-05
Mouse	anti-human IgG3	1:3,000	SouthernBiotech	9210-05
Mouse	anti-human IgG4	1:3,000	SouthernBiotech	9200-05
Mouse	anti-human IgG4	1:500	Invitrogen	A-10654

404

405 [Antigens used.](#)

406 See **Table 3**.

407 *Table 3. Antigens used.*

Antigen	Application	Source	Mutant amino acid residues	Coating concentration	Brand name/publication source	Product number
---------	-------------	--------	----------------------------	-----------------------	-------------------------------	----------------

spike ECD	ELISA	HEK293		1 µg /mL	(Emmenegger <i>et al.</i> , 2020), Oxford	
WT spike S1	ELISA	HEK293		1 µg /mL	AcroBiosystems	S1N-C52H2
WT spike S2	ELISA	HEK293		1 µg /mL	AcroBiosystems	S2N-C52H5
WT RBD	ELISA	HEK293		1 µg /mL	(Emmenegger <i>et al.</i> , 2020), Oxford	
WT RBD	MAAP	HEK293			Sino Biological	40592-V08H
Delta RBD	ELISA, MAAP	HEK293	L452R, T478K	1 µg /mL	Sino Biological	40592-V08H90
Omicron RBD	ELISA, MAAP	HEK293	G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H	1 µg /mL	Sino Biological	40592-V08H121
NC	ELISA	HEK293		1 µg /mL	AcroBiosystems	NUN-C5227

409 Supporting information

410 Acknowledgements

411 We are grateful to all the patients who enabled this study by means of signing the hospital-wide
412 general consent and thereby contributed to scientific understanding. We thank the high-throughput
413 serology team of the Institute of Neuropathology and the entire team of the Institute of Clinical
414 Chemistry for help with sample handling and machine maintenance, Dr. Sreedhar Saseendran Kumar
415 (BEL, ETH Zurich) for advice on statistical methods, Dr. Natascha Wuillemin (Mabylon AG, Schlieren)
416 for the provision of a reagent, and Dr. Vishalini Emmenegger (BEL, ETH Zurich) for support and
417 inspiration.

418 Funding statement

419 Institutional core funding by the University of Zurich and the University Hospital of Zurich, Swiss
420 National Science Foundation (SNF) grant #179040 as well as Driver Grant 2017DRI17 of the Swiss
421 Personalized Health Network to AA; funding by grants of Innovation Fund of the University Hospital
422 Zurich (INOV00096), and of the NOMIS Foundation, the Schwyzer Winiker Stiftung, and the Baugarten
423 Stiftung (coordinated by the USZ Foundation, USZF27101) to AA and ME as well as the USZ Foundation
424 USZF270808 to SDB.

425 Author contribution

426 Conceived the study: AKL, AA, SF, ME. Collected and annotated patient samples: SDB, TS, MR, LS, AvE,
427 ME. Performed MAAP experiments and analysed the respective data: SF, SRAD, ASM, FR, AI, AM, AKL,
428 TPJK. Performed TRABI experiments: LM, LB, AA, ME. Analysed the data: ME. Wrote the manuscript:
429 AA, ME. Read and revised the manuscript: all authors.

430 Competing Interest Statement

431 TPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the clinical and
432 scientific advisory board of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG.
433 AKL, SF, SRAD, ASM, AYM, AI, and FR are employees of Fluidic Analytics. All other authors declare no
434 competing interest.

435

436 References

- 437 Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K.,
438 Arunkumar, G. A., Jurczynszak, D., Polanco, J., *et al.* (2020) 'A serological assay to detect SARS-CoV-2
439 seroconversion in humans', *Nature Medicine*, 26(7), pp. 1033–1036. doi: 10.1038/s41591-020-0913-
440 5.
- 441 Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A.,
442 De Marco, A., di Iulio, J., *et al.* (2022) 'Broadly neutralizing antibodies overcome SARS-CoV-2
443 Omicron antigenic shift', *Nature*, 602(7898), pp. 664–670. doi: 10.1038/s41586-021-04386-2.
- 444 Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., *et al.*
445 (2021) 'Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies', *Nature*.
446 Available at: <https://doi.org/10.1038/s41586-021-04385-3> (Accessed: 27 February 2022).
- 447 Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D.,
448 Scheepers, C., Amoako, D. G., *et al.* (2021) 'Omicron extensively but incompletely escapes Pfizer
449 BNT162b2 neutralization', *Nature*. doi: 10.1038/S41586-021-04387-1.
- 450 Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M.,
451 Mentzer, A. J., Tuekprakhon, A., *et al.* (2022) 'SARS-CoV-2 Omicron-B.1.1.529 leads to widespread
452 escape from neutralizing antibody responses', *Cell*, 185(3), pp. 467-484.e15. doi:
453 10.1016/J.CELL.2021.12.046.
- 454 Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S., Pollard, A. J., Liu, X., Lambe, T., Crook,
455 D., Stuart, D. I., *et al.* (2021) 'Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by
456 post-immunisation serum', *Lancet*, 399(10321), pp. 234–236. doi: 10.1016/s0140-6736(21)02844-0.
- 457 Denninger, V., Xu, C. K., Meisl, G., Morgunov, A. S., Fiedler, S., Ilesley, A., Emmenegger, M., Malik, A.
458 Y., Piziorska, M. A., Schneider, M. M., *et al.* (2021) 'Understanding the role of memory re-activation
459 and cross-reactivity in the defense against SARS-CoV-2', *bioRxiv*, p. 2021.07.23.453352. doi:
460 10.1101/2021.07.23.453352.
- 461 Edara, V. V., Manning, K. E., Ellis, M., Lai, L., Moore, K. M., Foster, S. L., Floyd, K., Davis-Gardner, M.
462 E., Mantus, G., Nyhoff, L. E., *et al.* (2022) 'mRNA-1273 and BNT162b2 mRNA vaccines have reduced
463 neutralizing activity against the SARS-CoV-2 omicron variant', *Cell Reports Medicine*, 3(2). doi:
464 10.1016/j.xcrm.2022.100529.
- 465 Emmenegger, M., De Cecco, E., Lamparter, D., Jacquat, R. P. B., Ebner, D., Schneider, M. M.,
466 Condado Morales, I., Schneider, D., Dogancay, B., Guo, J., *et al.* (2020) 'Early peak and rapid decline
467 of SARS-CoV-2 seroprevalence in a Swiss metropolitan region', *medRxiv*. doi:
468 10.1101/2020.05.31.20118554.
- 469 Emmenegger, M., Saseendran Kumar, S., Emmenegger, V., Malinauskas, T., Buettner, T., Rose, L.,
470 Schierack, P., Sprinzl, M. F., Sommer, C. J., Lackner, K. J., *et al.* (2021) 'Anti-prothrombin
471 autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody
472 response against SARS-CoV-2 proteins', *PLOS Pathogens*, 17(12), p. e1010118. doi:
473 10.1371/JOURNAL.PPAT.1010118.
- 474 Farkash, I., Feferman, T., Cohen-Saban, N., Kirgner, I., Levin, Y., Dahan Correspondence, R., Avraham,
475 Y., Morgenstern, D., Mayuni, G., Barth, N., *et al.* (2021) 'Anti-SARS-CoV-2 antibodies elicited by
476 COVID-19 mRNA vaccine exhibit a unique glycosylation pattern', *Cell Reports*, 37. doi:
477 10.1016/j.celrep.2021.110114.
- 478 Fiedler, S., Devenish, S. R. A., Morgunov, A. S., Ilesley, A., Ricci, F., Emmenegger, M., Kosmoliaptsis, V.,
479 Theel, E. S., Mills, J. R., Sholukh, A. M., *et al.* (2022) 'Serological fingerprints link antiviral activity of

- 480 therapeutic antibodies to affinity and concentration', *bioRxiv*, p. 2022.02.03.478946. doi:
481 10.1101/2022.02.03.478946.
- 482 Fiedler, S., Piziorska, M. A., Denninger, V., Morgunov, A. S., Ilesley, A., Malik, A. Y., Schneider, M. M.,
483 Devenish, S. R. A., Meisl, G., Kosmoliaptsis, V., *et al.* (2021) 'Antibody Affinity Governs the Inhibition
484 of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum', *ACS Infectious Diseases*, 7(8), pp. 2362–2369.
485 doi: 10.1021/acsinfecdis.1c00047.
- 486 Han, Pengcheng, Li, L., Liu, S., Wang, Q., Zhang, D., Xu, Z., Han, Pu, Li, X., Peng, Q., Su, C., *et al.* (2022)
487 'Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta
488 SARS-CoV-2', *Cell*, 185(4), pp. 630-640.e10. doi: 10.1016/J.CELL.2022.01.001.
- 489 Jarlhelt, I., Nielsen, S. K., Jahn, C. X. H., Hansen, C. B., Pérez-Alós, L., Rosbjerg, A., Bayarri-Olmos, R.,
490 Skjoedt, M. O. and Garred, P. (2021) 'SARS-CoV-2 Antibodies Mediate Complement and Cellular
491 Driven Inflammation', *Frontiers in Immunology*, 12, p. 4612. doi:
492 10.3389/FIMMU.2021.767981/BIBTEX.
- 493 Klingler, J., Lambert, G. S., Itri, V., Liu, S., Bandres, J. C., Enyindah-Asonye, G., Liu, X., Simon, V.,
494 Gleason, C. R., Kleiner, G., *et al.* (2021) 'Detection of Antibody Responses Against SARS-CoV-2 in
495 Plasma and Saliva From Vaccinated and Infected Individuals', *Frontiers in Immunology*, 12, p. 5382.
496 doi: 10.3389/FIMMU.2021.759688/BIBTEX.
- 497 Kober, C., Manni, S., Wolff, S., Barnes, T., Mukherjee, S., Vogel, T., Hoenig, L., Vogel, P., Hahn, A.,
498 Gerlach, M., *et al.* (2022) 'IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in
499 Convalescent Plasma Pools', *PLOS ONE*, 17(1), p. e0262162. doi: 10.1371/JOURNAL.PONE.0262162.
- 500 Linse, S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., Sileikis, E.,
501 Lundqvist, M., Qian, F., O'Malley, T., *et al.* (2020) 'Kinetic fingerprints differentiate the mechanisms
502 of action of anti-A β antibodies', *Nature Structural & Molecular Biology*, 27(12), pp. 1125–1133. doi:
503 10.1038/s41594-020-0505-6.
- 504 Liu, Lihong, Iketani, S., Guo, Y., Chan, J. F. W., Wang, M., Liu, Liyuan, Luo, Y., Chu, H., Huang, Yiming,
505 Nair, M. S., *et al.* (2022) 'Striking antibody evasion manifested by the Omicron variant of SARS-CoV-
506 2', *Nature*, 602(7898), pp. 676–681. doi: 10.1038/s41586-021-04388-0.
- 507 Mattiuzzo, G., Bentley, E. M., Hassall, M., Routley, S., Richardson, S., Bernasconi, V., Kristiansen, P.,
508 Harvala, H., Roberts, D., Semple, M. G., *et al.* (2020) 'Establishment of the WHO International
509 Standard and Reference Panel for anti-SARS-CoV-2 antibody', *World Health Organization*, 60.
- 510 Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W. H.,
511 Porrot, F., Staropoli, I., Lemoine, F., *et al.* (2021) 'Considerable escape of SARS-CoV-2 Omicron to
512 antibody neutralization', *Nature 2021 602:7898*, 602(7898), pp. 671–675. doi: 10.1038/s41586-021-
513 04389-z.
- 514 Schneider, M. M., Emmenegger, M., Xu, C. K., Morales, I. C., Meisl, G., Turelli, P., Zografou, C.,
515 Zimmermann, M. R., Frey, B. M., Fiedler, S., *et al.* (2022) 'Microfluidic characterisation reveals broad
516 range of SARS-CoV-2 antibody affinity in human plasma', *Life Science Alliance*, 5(2), p. e202101270.
517 doi: 10.26508/LSA.202101270.
- 518 Sievers, B. L., Chakraborty, S., Xue, Y., Gelbart, T., Gonzalez, J. C., Cassidy, A. G., Golan, Y., Prah, M.,
519 Gaw, S. L., Arunachalam, P. S., *et al.* (2022) 'Antibodies elicited by SARS-CoV-2 infection or mRNA
520 vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses', *Science
521 Translational Medicine*. doi: 10.1126/SCITRANSLMED.ABN7842.
- 522 Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H.,
523 Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., *et al.* (2020) 'Rapid Generation of

524 Neutralizing Antibody Responses in COVID-19 Patients', *Cell Reports Medicine*, 1(3), p. 100040. doi:
525 10.1016/J.XCRM.2020.100040.

526 VanBlargan, L. A., Errico, J. M., Halfmann, P. J., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y.,
527 Corti, D., Fremont, D. H. and Diamond, M. S. (2022) 'An infectious SARS-CoV-2 B.1.1.529 Omicron
528 virus escapes neutralization by therapeutic monoclonal antibodies', *Nature Medicine*, pp. 1–6. doi:
529 10.1038/s41591-021-01678-y.

530

531

532

533

534 Supplementary figure legends

535

536 **Figure S1. Reactivity profile for Spike and NC and correlations between three repeat IgG4**
537 **measurements, using two different secondary antibodies. A.** Violin plot showing the reactivity profile
538 for spike ECD. All IgG subtypes contribute to the reactivity, except IgG2. IgM are generally low. **B.** Violin
539 plot showing the reactivity profile for NC protein. The dominant subtype is IgG3. (A) and (B):
540 Infected/vaccinated patients are in grey, infected/non-vaccinated patients are in blue, and non-
541 infected/vaccinated patients are in yellow. **C.** $p(EC_{50})$ values of the first IgG4 measurements versus
542 $p(EC_{50})$ values of the second IgG4 measurements. The same secondary antibodies were used. Data are
543 pooled for all antigens. **D.** $p(EC_{50})$ values of the first IgG4 measurements versus $p(EC_{50})$ values of the
544 third IgG4 measurements. For the third measurement, a different secondary antibody was used. Data
545 are pooled for all antigens.

546

547 **Figure S2. Correlations among RBD variants, the WT spike ectodomain, and comparison of RBD**
548 **variants. A.** $p(EC_{50})$ WT RBD versus $p(EC_{50})$ delta RBD. **B.** $p(EC_{50})$ WT RBD versus $p(EC_{50})$ omicron RBD.
549 **C.** $p(EC_{50})$ delta RBD versus $p(EC_{50})$ omicron RBD. **D.** $p(EC_{50})$ WT spike ectodomain versus $p(EC_{50})$ WT
550 RBD. Shapes indicate the different patient groups. **E.** Mean $p(EC_{50})$ values of all immunoglobulin iso-
551 and subtypes for WT (grey), delta (blue), and omicron (yellow) RBD variants are shown in a radar plot.

552

553 **Figure S3. Correlation of MAAP data with ELISA titers.** K_A (A), IgG concentration (B), and the product
554 of $K_A \times$ IgG concentration (C) were plotted against the respective ELISA $p(EC_{50})$ values obtained for WT,
555 delta, and omicron RBD variants. The shapes indicate the respective patient groups, as is shown in the
556 main figure.

557

558 **Figure S4. Variables of PCA shown in main figure.** The variables of the PCA representations from the
559 main figures are displayed in detail. **A.** PCA including REGN-COV-treated patients. **B.** PCA excluding
560 REGN-COV-treated patients.

561

562 **Figure S5. Correlogram representation of all correlations without restriction by statistical**
563 **significance.** Correlogram analysis using the TRABI ELISA values combined with features such as
564 disease severity, immunosuppression, number of vaccinations received, sex, and age.

565

566

567 *Table 1. Basic demographic features of cohort.*

TABLE 1	N	FEMALE	MALE	AGE (MEDIAN, IQR), YEARS	REGN-COV-TREATED
ALL INDIVIDUALS	41	17	24	65, 54-77	5
NON-INFECTED/NON-VACCINATED	2	1	1	58.5, 58.25-58.75	0
INFECTED/NON-VACCINATED	8	4	4	61, 53-66	1
NON-INFECTED/VACCINATED	20	8	12	63, 57-78	0
INFECTED/VACCINATED	11	4	7	74, 61-84	4

568

569





Fig. S1

570

571



572

573

Fig. S2





Fig. S3

574

575



576

577




Fig. S5